Department of Orthopedics, The First People's Hospital of Wujiang District, Suzhou, China.
Eur Rev Med Pharmacol Sci. 2018 Sep;22(17):5460-5470. doi: 10.26355/eurrev_201809_15806.
To investigate the role of microRNA-337-5p in osteosarcoma (OS) and its underlying mechanism.
The microRNA (microRNA-337-5p) that may be related to OS development was screened out by GEO (Gene Expression Omnibus) database. Survival analysis and ROC curve were performed according to microRNA-337-5p expressions in OA patients. Besides, the correlation between microRNA-337-5p expression and clinical parameters was evaluated by Chi-square analysis. Cox regression analysis was performed to detect the relationship between the overall survival and clinical parameters of OA patients. Subsequently, enriched functions and pathways of microRNA-337-5p were predicted by GESA (gene enrichment sets analysis). MicroRNA-337-5p expression was detected in 65 OS tissue samples and 30 normal tissue samples by qRT-PCR (quantitative Real-Time Polymerase Chain Reaction). For in vitro experiments, after microRNA-337-5p mimics or microRNA-337-5p inhibitor was transfected into OS cells, proliferative and invasive abilities were detected by CCK-8 (Cell Counting Kit-8) and transwell assay, respectively. Finally, Western blot was used to explore the underlying mechanism of microRNA-337-5p in regulating OS.
MicroRNA-337-5p was overexpressed in serum and tissue samples of OS patients, which was valuable in diagnosing OS. Besides, microRNA-337-5p expression was correlated with the overall survival and necrosis range of OA patients, whereas not correlated with age and sex. GESA indicated that microRNA-337-5p was enriched in ERBB, MAPK, and VEGF pathways. In vitro experiments indicated elevated proliferative and invasive abilities in MG63 and U2OS cells after microRNA-337-5p overexpression. Furthermore, increased expressions of ERBB2, Erk1/2, and VEGF121 were observed in OS cells after microRNA-337-5p overexpression.
MicroRNA-337-5p is upregulated in OS tissues, which is an independent prognostic factor in OS. Overexpressed microRNA-337-5p can promote proliferative and invasive abilities of OS cells via activating ERBB, MAPK, and VEGF pathways.
探讨微小 RNA-337-5p 在骨肉瘤（OS）中的作用及其机制。
通过 GEO（基因表达综合数据库）数据库筛选出可能与 OS 发生发展相关的 microRNA（miR-337-5p）。根据 OA 患者 miR-337-5p 的表达进行生存分析和 ROC 曲线分析。此外，通过卡方分析评估 miR-337-5p 表达与临床参数的相关性。采用 Cox 回归分析检测 OS 患者总体生存率与临床参数的关系。随后，通过 GESA（基因富集集分析）预测 miR-337-5p 的富集功能和通路。通过 qRT-PCR（实时定量聚合酶链反应）检测 65 例 OS 组织样本和 30 例正常组织样本中的 miR-337-5p 表达。进行体外实验，转染 miR-337-5p 模拟物或 miR-337-5p 抑制剂后，通过 CCK-8（细胞计数试剂盒-8）和 Transwell 实验分别检测 OS 细胞的增殖和侵袭能力。最后，通过 Western blot 探讨 miR-337-5p 调节 OS 的潜在机制。
OS 患者血清和组织样本中 miR-337-5p 表达上调，对 OS 有诊断价值。此外，miR-337-5p 表达与 OS 患者的总生存率和坏死范围相关，而与年龄和性别无关。GESA 表明，miR-337-5p 富集于 ERBB、MAPK 和 VEGF 通路。体外实验表明，miR-337-5p 过表达后，MG63 和 U2OS 细胞的增殖和侵袭能力增强。此外，miR-337-5p 过表达后 OS 细胞中 ERBB2、Erk1/2 和 VEGF121 的表达增加。
miR-337-5p 在 OS 组织中上调，是 OS 的独立预后因素。过表达的 miR-337-5p 可通过激活 ERBB、MAPK 和 VEGF 通路促进 OS 细胞的增殖和侵袭能力。
